Dose-response effect of single and combined clofibrate (Atromidin®) and niceritrol (perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia

Olsson, Anders; Oro, R. Dell; Rössner, Stephan

doi:10.1016/0021-9150(75)90070-2

Cited by 17 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Effects of 3‐Hydroxy‐3‐methylglutaric Acid on Plasma and Low‐Density Lipoprotein Cholesterol Levels in Familial Hypercholesterolemia

Lupien

Moorjani

Brun

et al. 1979

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Different doses of 3-hydroxy-3-methyl-glutaric acid (HMG) on plasma lipids were studied in a double-blind trial in 36 patients with familial hypercholesterolemia (type IIa or hyper-beta-lipoproteinemia). The patients were randomly assigned to five groups, and each group received one of the following treatments: placebo, or HMG 750 mg, 1500 mg, 2250 mg, or 3000 mg per day. As compared to placebo, the mean plasma cholesterol levels during the eight-week treatment period were 11 and 13 per cent lower in the 2250-mg and 3000-mg HMG-treated groups (P less than 0.034 and less than 0.021, respectively). At the same dosage levels LDL cholesterol was decreased by 8 per cent. HMG had no significant effect on plasma triglycerides as compared to placebo. Discontinuation of the medication did not result in a rebound of plasma cholesterol. There were no clinical or biologic adverse effects due to the administration of HMG, and all patients maintained excellent compliance to the medication. Because of its lack of toxicity, HMG may be useful as an adjunct to diet in the treatment of familial hypercholesterolemia.

show abstract

Effects of 3‐Hydroxy‐3‐methylglutaric Acid on Plasma and Low‐Density Lipoprotein Cholesterol Levels in Familial Hypercholesterolemia

Lupien

Moorjani

Brun

et al. 1979

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

The Drug Treatment of Hyperlipidemia

Jones

1977

Atherosclerosis

View full text Add to dashboard Cite

Lack of effect in vivo of clofibrate on adrenal steroid secretion

Heshmati

Turpin

Touitou

et al. 1989

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Clofibrate inhibits the synthesis of adrenal steroids when administered in vitro. In the present study the effect in vivo of clofibrate on adrenal steroid secretion has been investigated. Basal levels of plasma progesterone, corticosterone, aldosterone, 17-hydroxyprogesterone, 11-deoxycortisol, cortisol, dehydroepiandrosterone sulphate and dehydroepiandrosterone, and their response to ACTH 1 mg im, were not reduced by chronic administration of clofibrate 2 g per day p.o. for 8 to 34 days to 6 hyperlipidaemic men.

show abstract

Dose-response effect of single and combined clofibrate (Atromidin®) and niceritrol (perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemia

Cited by 17 publications

References 10 publications

Effects of 3‐Hydroxy‐3‐methylglutaric Acid on Plasma and Low‐Density Lipoprotein Cholesterol Levels in Familial Hypercholesterolemia

Effects of 3‐Hydroxy‐3‐methylglutaric Acid on Plasma and Low‐Density Lipoprotein Cholesterol Levels in Familial Hypercholesterolemia

The Drug Treatment of Hyperlipidemia

Lack of effect in vivo of clofibrate on adrenal steroid secretion

Contact Info

Product

Resources

About